Enanta Pharmaceuticals, Inc. (ENTA)
12.11
-0.09
(-0.74%)
USD |
NASDAQ |
Sep 21, 16:00
12.11
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Price to Book Value : 3.489 for Sept. 21, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 3.489 |
| September 18, 2026 | 3.515 |
| September 17, 2026 | 3.607 |
| September 16, 2026 | 3.659 |
| September 15, 2026 | 3.541 |
| September 14, 2026 | 3.780 |
| September 11, 2026 | 3.734 |
| September 10, 2026 | 3.659 |
| September 09, 2026 | 3.815 |
| September 08, 2026 | 3.890 |
| September 04, 2026 | 4.057 |
| September 03, 2026 | 4.040 |
| September 02, 2026 | 4.060 |
| September 01, 2026 | 3.892 |
| August 31, 2026 | 3.841 |
| August 28, 2026 | 3.918 |
| August 27, 2026 | 3.976 |
| August 26, 2026 | 4.077 |
| August 25, 2026 | 4.057 |
| August 24, 2026 | 4.062 |
| August 21, 2026 | 3.881 |
| August 20, 2026 | 3.783 |
| August 19, 2026 | 3.892 |
| August 18, 2026 | 3.832 |
| August 17, 2026 | 3.697 |
| Date | Value |
|---|---|
| August 14, 2026 | 3.792 |
| August 13, 2026 | 3.872 |
| August 12, 2026 | 3.890 |
| August 11, 2026 | 3.895 |
| August 10, 2026 | 3.979 |
| August 07, 2026 | 3.968 |
| August 06, 2026 | 3.844 |
| August 05, 2026 | 3.809 |
| August 04, 2026 | 3.838 |
| August 03, 2026 | 3.731 |
| July 31, 2026 | 3.630 |
| July 30, 2026 | 3.746 |
| July 29, 2026 | 3.587 |
| July 28, 2026 | 3.633 |
| July 27, 2026 | 3.668 |
| July 24, 2026 | 3.682 |
| July 23, 2026 | 3.731 |
| July 22, 2026 | 3.763 |
| July 21, 2026 | 3.867 |
| July 20, 2026 | 3.792 |
| July 17, 2026 | 3.959 |
| July 16, 2026 | 3.800 |
| July 15, 2026 | 3.812 |
| July 14, 2026 | 3.777 |
| July 13, 2026 | 3.93 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Perspective Therapeutics, Inc. | 1.046 |
| AbbVie, Inc. | -- |
| Coherus Oncology, Inc. | 3.478 |
| BridgeBio Pharma, Inc. | -- |
| RenovoRx, Inc. | 8.392 |
Price to Book Value Related Metrics
| PS Ratio | 5.022 |
| Price | 12.11 |
| Earnings Yield | -19.91% |
| Market Cap | 352.64M |